



Pediatric Atopic Dermatitis: Clinical Scenarios

Clinical Brief #1 – Infants with Moderate to Severe AD

References

Tweet 2 Reference:

Paller AS, Simpson EL, Siegfried EC, et al. Dupilumab in children aged 6 months to younger than 6 years with uncontrolled atopic dermatitis: a randomized, double-blind, placebo-controlled, phase 3 trial. *Lancet*. 2022;400:908-919.

Additional References:

Allergy and Asthma Network (AAN). Eczema (atopic dermatitis) statistics. Accessed March 31, 2023. <https://allergyasthmanetwork.org/what-is-eczema/eczema-statistics/>

Eichenfield LF, Stripling S, Fung S, Cha A, O'Brien A, Schachner LA. Recent developments and advances in atopic dermatitis: a focus on epidemiology, pathophysiology, and treatment in the pediatric setting. *Pediatric Drugs*. 2022;24:293-305.

Paller AS, Antila M, Marcoux D, et al. The patient burden of moderate-to-severe atopic dermatitis (AD) in children aged <12 years: results from 732 patients in the PEDiatric STudy in Atopic Dermatitis (PEDISTAD) observational study. *J Allergy Clin Immunol*. 2022;149(Suppl):Abstract 023.

Paller AS, Guttman-Yassky E, Schuttelaar MLA, et al. Disease characteristics, comorbidities, treatment patterns and quality of life impact in children <12 years old with atopic dermatitis: Interim results from the PEDISTAD Real-World Registry. *J Am Acad Dermatol*. 2022;87:1104-1108.

Paller AS, Mina-Osorio P, Vekeman F, et al. Prevalence of type 2 inflammatory diseases in pediatric patients with atopic dermatitis: Real-world evidence. *J Am Acad Dermatol*. 2022;86:758-765.

Glossary

AD, atopic dermatitis
IGA, Investigators' Global Assessment score
MO, month old
PEDISTAD, PEDiatric STudy in Atopic Dermatitis
TCS, topical corticosteroid(s)
TEAEs, treatment-emergent adverse events
w/, with
YO, year old